Phase I Clinical Trial Using [Tc]Tc-1-thio-D-glucose for Diagnosis of Lymphoma Patients.

Similar to [F]-FDG, [Tc]Tc-1-thio-D-glucose ([Tc]Tc-TG) also binds to GLUT receptors. The aim of this Phase I study was to evaluate the safety, biodistribution and dosimetry of [Tc]Tc-TG. Twelve lymphoma patients were injected with 729 ± 102 MBq [Tc]Tc-TG.